- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03967795
Citrullinemia for the Prediction of Enteral Nutrition Tolerance Among Critically Ill Patients (PREDICT)
The French intensive care societies (SRLF and SFAR), in agreement with the European and American societies for enteral and parenteral nutrition, recommend to quickly administer an artificial nutrition to patients admitted to ICU and for which it is expected that they will not be able to eat normally in the three days of admission.
Enteral nutrition should be used in priority if the gut is functioning. However, intolerance to enteral nutrition, such as vomiting, regurgitation, increased residual gastric volume, or diarrhea, occurs in 40% of patients hospitalized in ICU receiving enteral nutrition. Intolerance to enteral nutrition leads to the risk of not receiving enough nutrition. Feeding intolerance also exposes to the risk of acute mesenteric ischemia, especially in the most severe patients under catecholamine for shock. Currently, it is not possible to predict intolerance to enteral nutrition in ICU patients. Thus, the diagnosis of intolerance is made a posteriori while enteral nutrition is in progress.
Citrullinemia (normal concentration of 20 to 60 μmol / L), could be a good biomarker of the function of enterocytes involved in the absorption of food.
The aim of this study is to evaluate the interest of citrullinemia to predict tolerance to enteral nutrition in ICU patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Citrulline is an amino acid mainly produced by enterocytes from glutamine.
Citrullinemia ≤ 20μmol/L is a biomarker of enterocyte mass reduction, secondary to the reduction of small bowel length or secondary to villous atrophy diseases. A patient with low citrullinemia is probably at risk of enteral nutrition malabsorption.
Citrulline generation test consists of measuring the course of citrullinemia after an oral or intravenous administration of glutamine, the main precursor of citrulline. When the small bowel is functional, administration of glutamine is followed by the elevation of citrullinemia. On the contrary, when there is enterocyte dysfunction or reduction, citrullinemia does not vary after glutamine administration. Peeters et al have shown the feasibility of carrying out the citrulline generation test in patients hospitalized in the ICU. In this context, intravenous administration of glutamine (20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, IV infusion over 30 minutes) followed by monitoring of citrullinemia (basal time and then after 90 minutes, on arterial sampling) is feasible and reproducible.
There is currently no data available on the relationship between citrullinemia measured at ICU admission and tolerance to enteral nutrition in the days following ICU admission. Similarly, the value of the citrulline generation test for evaluating enteral nutrition tolerance is unknown.
The investigators hypothesize that patients with low citrullinemia at ICU admission, as well as those with a decreased citrullinemia elevation after Dipeptiven bolus, will have less tolerance to enteral nutrition than patients with normal citrullinemia.
PREDICT is the first study evaluating the interest of citrullinemia and the citrulline generation test to predict feeding tolerance among critically ill patients.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gaël PITON, MD
- Phone Number: +33 381668127
- Email: gpiton@chu-besancon.fr
Study Contact Backup
- Name: Lucie VETTORETTI, PhD
- Phone Number: +33381218378
- Email: lvettoretti@chu-besancon.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years old or older
- patient admited to ICU
- expected hospital stay of at least 3 days
- indication of enteral nutrition.
- presence of an arterial catheter
- signed informed consent
Exclusion Criteria:
- contraindication to enteral nutrition (e.g. non-functional digestive tract, mesenteric ischemia, occlusion, digestive fistula, active gastrointestinal bleeding)
- pregnancy ;
- chronic renal failure;
- chronic intestinal pathology
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: All patients
Citrulline genration test before starting enteral nutrition At ICU admission, a blood sample is collected (i) before and (ii) 90 minutes after N2-L-Alanyl-L-Glutamine administration |
20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feeding intolerance at day-3 and citrulline generation test
Time Frame: Day 3
|
Feeding intolerance evaluated at day-3 of enteral nutrition Citrulline generation test: variation of citrullinemia/90 minutes
|
Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feeding intolerance at dat 3 and basal plasma citrulline
Time Frame: Day 3
|
Feeding intolerance at day-3 of enteral nutrition Citrullinemia measured the first day just before initiation of enteral nutrition
|
Day 3
|
Citrullinemia and cumulative amount of enteral nutrition
Time Frame: Day 3
|
Link between citrullinemia and cumulative amount of enteral nutrition administred during the first three days of ICU stay
|
Day 3
|
Citrullinemia and enteral nutrition complications occurrence
Time Frame: First week
|
Link between citrullinemia levels and occurrence of acute mesenteric ischemia and inhalation pneumopathy during the first week of enteral nutrition
|
First week
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gaël PITON, MD, CHU de Besancon
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- API/2018/93
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biomarkers
-
Peking UniversityCompleted
-
University of MinnesotaCompleted
-
University of California, DavisUSDA, Western Human Nutrition Research CenterRecruiting
-
Harvard School of Public Health (HSPH)CompletedBiomarkersUnited States
-
West China HospitalRecruitingBiomarkers | NeonateChina
-
U.S. Army Medical Research and Development CommandWalter Reed Army Institute of Research (WRAIR)CompletedBiomarkers, PharmacologicalUnited States
-
Five Liters, Inc.Northwell Health; The Feinstein Institutes for Medical ResearchRecruitingHemostasis | Blood BiomarkersUnited States
-
CareDxRecruitingLiver Transplantation | BiomarkersUnited States
-
Washington State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedInteraction | Endogenous BiomarkersUnited States
-
Claudine MANACHNational Research Agency, FranceCompletedBiomarkers | Food IntakeFrance
Clinical Trials on N2-L-Alanyl-L-Glutamine (Substance)
-
University Hospital MuensterFresenius Kabi; IZKF (Interdisciplinary Centre for Clinical Research (IZKF)...CompletedAcute Kidney Injury | Cardiac SurgeryGermany
-
Scandinavian Critical Care Trials GroupTerminated
-
Instituto Mexicano del Seguro SocialCompletedInsufficiency;CardiacMexico
-
Temple Therapeutics BVCompletedPelvic AdhesionsUkraine
-
National Cardiovascular Center Harapan Kita Hospital...CompletedCoronary Artery Disease | Coronary Artery Bypass | Cardiopulmonary BypassIndonesia
-
Emmaus Medical, Inc.Completed
-
Hawaii Pacific HealthUnknown
-
Southwest Oncology GroupNational Cancer Institute (NCI)TerminatedPain | Head and Neck Cancer | Cancer-related Problem/ConditionCanada, United States
-
Emmaus Medical, Inc.FDA Office of Orphan Products DevelopmentCompletedSickle Cell Anemia | ThalassemiaUnited States
-
Meshalkin Research Institute of Pathology of CirculationCompletedCoronary Artery DiseaseRussian Federation